0310 ECP Ventyx
BioCentury & Getty Images

Emerging Company Profile

Ventyx emerges with $114M to bring asset-centric immunology plays under one umbrella

Emerging Company Profile: Oppilan, Zomagen and Ventyx merge to advance autoimmune, inflammation pipeline

Oppilan, Zomagen and Ventyx merge to advance autoimmune and inflammation pipeline with $114 million round led by venBio. 

Mar 11, 2021 | 1:16 AM GMT

Ventyx is the second start-up in the past month to bundle asset-centric companies under one umbrella with an eye towards advancing each program faster than the originator companies could have had they remained independent. The company, which launched Tuesday

Read the full 943 word article

How to gain access

Continue reading with a
two-week free trial.